

# **IASLC WCLC Press Program and Press Releases**

**Saturday, September 7th Press Briefing – 16:00-17:30, in front of mobile CT unit just outside plenary hall**

**Moderator: Dave Mesko**

- Welcome from co-chairs, R. Rami-Porta and T. Rosell
- 20<sup>th</sup> WCLC highlights, include infographic. P. Bunn
- STARS Program Announcement, STARS winner (C. Egwuenu), mentor (U.Basu Roy) and surgeon (B. Stiles)
- IASLC Molecular Testing Survey, M. Smeltzer
- IASLC Tobacco Declaration J. Jassem
- Lung Ambition Alliance, G. Scagliotti with IASLC, AstraZeneca, GLCC and Guardant

**Sunday, Sept. 8th Press Briefing – 09:45-10:30**

**Moderator: Enriqueta Felip**

- Summary of day's plenary (5 mins) and any key highlights/themes – E. Felip
- Announcement of JTO Clinical and Research Reports -- A. Adjei
- Phase 1 Study of Safety, Tolerability, P--K and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC -- R. Govindan
- Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial -- N. Rizvi
- CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC -- F. Barlesi
- Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC -- M. Garassino
- KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC -- C. Langer

## **Monday, Sept 9th (Presidential Symposium Press Briefing) – 10:15-11:00**

### **Moderator: Giorgio Scagliotti**

- Summary of day's plenary (5 mins) and any key highlights/themes – G. Scagliotti
- Lung Cancer Screen Selection by USPSTF Versus PLCOM2012 Criteria – Interim ILST Finding -- S. Lam
- Early Detection of Cancer of the Lung Scotland (ECLS): Trial Results -- F. Sullivan
- Blood MicroRNA and LDCT Reduce Unnecessary LDCT Repeats in Lung Cancer Screening: Results of Prospective BioMILD -- U. Pastorino
- In Hospital Clinical Efficacy, Safety and Oncologic Outcomes from VIOLET: A UK Multi-Centre RCT of VATS Versus Open Lobectomy for Lung Cancer -- E. Lim
- Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers -- A. Drilon
- National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC) -- G. Middleton
- Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study -- L. Paz-Ares

## **Tuesday, Sept 10th Press Briefing – 10:45-11:30**

### **Moderator: Toni Rosell**

- Summary of day's plenary (5 mins) and any key highlights/themes – T. Rosell
- KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer -- M. Reck
- IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC -- F. Cappuzzo
- Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC-- S. Gettinger
- Challenges in Lung Cancer Clinical Trials: A European Perspective -- A.M. Baird
- PL 03: Establishing a Nurse Led Follow-Up Service for Patients With Resected Early Stage Lung Cancer -- J. Mitchell

### ***Sunday Press Releases for Consideration***

- Randomized Clinical Trial with Computer Assisted Diagnosis (CAD) Versus Radiologist as First Reader of Lung Screening LDCT -- R. Yuan
- Evaluation of the Clinical Utility of the PanCan, EU-NELSON and Lung-RADS Protocols for Management of Screen Detected Lung Nodules at Baseline -- R. Myers
- Transforming the Patient Experience in Lung Cancer Through the Use of Clinical Nurse Specialist Virtual Clinics - The Liverpool Experience -- A.V. McIver (Sunday)

### ***Monday Press Releases for Consideration***

- Patient Knowledge and Expectations Related to Return of Genomic Results in the Lung-MAP (SWOG 1400) Biomarker-Driven Clinical Trial -- J. Roth
- Lung Cancer as a Second Primary Malignancy Among Women with Breast Cancer: The Role of Hormone Replacement and Smoking -- J. Bodor
- The Role of Simulation Modeling in Shaping Lung Cancer Screening Policies in the US and Elsewhere -- R. Meza
- Residential Radon, Smoking and Lung Cancer Risk. A Case-Control Study in a Radon Prone Area -- A. Ruano-Ravina
- Opt-Out Smoking Cessation Program in Lung Cancer Screening Provides Excellent Quit Rates -- R. Myers
- Quality of Life (QoL) Analysis in Lung Cancer: A Systematic Review of Phase III Trials Published Between 2012 and 2018 -- M.L. Reale

### ***Tuesday Press Releases For Consideration:***

- Global Quantitative Mass Spectrometry Reveals Potential Novel Actionable Targets in Thymic Epithelial Tumors (TET) -- X. Zhang<sup>1</sup>
- Clinical Rationale and Preclinical Evidence for Chimeric Antigen Receptor (CAR) T Cell Therapy Clinical Trial in KRAS-Mutant Lung Cancer -- J. Minehart
- Challenging Negative Stereotypes Around Lung Cancer in Ireland -- A.M. Baird
- NADIM Study: Updated Clinical Research and Outcome -- B. Sepesi
- Closing remarks/conference highlights